Cleveland Clinic Foundation; and.
Harrington Heart & Vascular Institute, University Hospitals Cleveland Medical Center, Case Cardiovascular Research Institute, Case Western Reserve University School of Medicine, Cleveland, OH.
Blood. 2018 Apr 26;131(17):1899-1902. doi: 10.1182/blood-2017-10-784074. Epub 2018 Feb 21.
Current antithrombotic drugs, including widely used antiplatelet agents and anticoagulants, are associated with significant bleeding risk. Emerging experimental evidence suggests that the molecular and cellular mechanisms of hemostasis and thrombosis can be separated, thereby increasing the possibility of new antithrombotic therapeutic targets with reduced bleeding risk. We review new coagulation and platelet targets and highlight the interaction between integrin αβ (Mac-1, CD11b/CD18) on leukocytes and GPIbα on platelets that seems to distinguish thrombosis from hemostasis.
目前的抗血栓药物，包括广泛使用的抗血小板药物和抗凝剂，都与显著的出血风险相关。新兴的实验证据表明，止血和血栓形成的分子和细胞机制可以分离，从而增加了具有降低出血风险的新型抗血栓治疗靶点的可能性。我们回顾了新的凝血和血小板靶点，并强调了白细胞上的整合素 αβ（Mac-1、CD11b/CD18）与血小板上的 GPIbα 之间的相互作用，这种相互作用似乎可以区分血栓形成和止血。
